Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

Inclusion Criteria

• •untreated early HR+ HER2- BC:
• •1. planned neoadjuvant chemotherapy: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
• •2. TanyN1-3M0 Ki67\>40% G3
• •3. ECOG 0-1
• •untreated early HR+ HER2- BC:
• •1. TanyN0M0 Ki67\<20% G1
• •2. ECOG 0-1
• •3. planned induction endocrine therapy (letrozole/anastrazole/tamoxifen)
• •untreated locally-advanced and/or borderline resectable pancreas cancer:
• •1. planned (neo)adjuvant chemotherapy: mFOLFIRINOX
• •2. previous surgery ( only R0 resection) is allowed
• •3. ECOG 0-1
• •4. histology diagnosis verification
• •Informed consent
• •Eligible blood\&fecal samples and tumor tissue for different time points